Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
affinity-enhanced NY-ESO-1 TCR T cells
- Development stage
- Approved
- Lead developer
- Adaptimmune Therapeutics
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Affinity-enhanced NY-ESO-1 TCR T-cell therapy is an adoptive cell therapy modality in which a patient's autologous T cells are genetically engineered to express a high-affinity T-cell receptor (TCR) specific for the NY-ESO-1 (CTAG1B) cancer-testis antigen. Naturally occurring TCRs against tumor antigens often have low affinity due to central tolerance; these engineered TCRs are modified in their complementarity-determining regions (CDRs) to enhance binding avidity to the NY-ESO-1 peptide presented by HLA-A*02. This approach allows the T cells to effectively recognize and kill tumor cells expressing NY-ESO-1. Key developers include Adaptimmune Therapeutics (afamitresgene autoleucel) and GSK (letetresgene autoleucel). The therapy has shown significant efficacy in solid tumors like synovial sarcoma and myxoid/round cell liposarcoma, as well as hematologic malignancies like multiple myeloma.
- Brand names
- Tecelra
- Other names
- afamitresgene autoleucelletetresgene autoleucelafami-cellete-celNY-ESO-1 TCR T-cellsNY-ESO1 TCR T-cellsNY-ESO 1 TCR T-cells
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on affinity-enhanced NY-ESO-1 TCR T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on affinity-enhanced NY-ESO-1 TCR T cells.